In summary, low CDC20 expression and higher CD8+ T cell infiltration along with upregulated PD-1 expression may benefit ACC patients in immunotherapy, providing important support for evaluating immunotherapy in ACC patients. This evidence concerns the gene CDC20 and adrenal cortex carcinoma.